Please login to the form below

Not currently logged in
Email:
Password:

GSK’s consumer health spin-off Haleon starts trading with £31bn market valuation

The company finalised its demerger of the Consumer Healthcare business group to form the new organisation

GSK

GSK has announced the finalisation of its demerger from the Consumer Healthcare business group to form its new consumer health group, Haleon. The spin-out began trading at the London Stock Exchange with a market valuation of around £31bn ($37bn).

The new company has annual sales of an estimated £10bn from over-the-counter products like Sensodyne toothpaste, Voltaren, Panadol and Centrum multivitamins, consolidating its position as the second-biggest global consumer health company.

GSK shareholders hold around 54.5% of Haleon, while the spin-out continues to hold a 13.5% share.

Pfizer, GSK’s partner in Haleon, holds the remaining 32% of shares in the new company and confirmed that it plans to sell its share now that the demerger has been finalised.

In January 2022, GSK rejected a $68bn bid from Unilever for the consumer health operations, stating that Unilever’s offer ‘fundamentally undervalued the Consumer Healthcare business and its future prospects’.

The demerger of Haleon from GSK follows years of planning and a vote in favour of the move by GSK shareholders.

Previously, GSK stated its plans to sell its share in Haleon in a 'disciplined manner' to raise money that will be invested into its R&D pipeline.

GSK has stated that it would begin a share consolidation in an effort to curb the impact of the spin-off on its stock.

Haleon is led by chief executive officer Brian McNamara who managed the joint venture when it was still part of GSK.

Article by
Fleur Jeffries

18th July 2022

From: Sales

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
SEVEN STONES COLLECTIVE

Hello. We are the Total Health creative agency. It’s our collective mix of talent that gets us to truly different...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...